ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · IEX Real-Time Price · USD
31.31
-0.08 (-0.24%)
At close: Dec 29, 2023, 4:00 PM
32.00
+0.69 (2.20%)
After-hours: Dec 29, 2023, 7:18 PM EST
ACADIA Pharmaceuticals Revenue
ACADIA Pharmaceuticals had revenue of $631.89M in the twelve months ending September 30, 2023, with 23.54% growth year-over-year. Revenue in the quarter ending September 30, 2023 was $211.70M with 61.96% year-over-year growth. In the year 2022, ACADIA Pharmaceuticals had annual revenue of $517.24M with 6.83% growth.
Revenue (ttm)
$631.89M
Revenue Growth
+23.54%
P/S Ratio
8.14
Revenue / Employee
$1,229,350
Employees
514
Market Cap
5.14B USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 517.24M | 33.09M | 6.83% |
| Dec 31, 2021 | 484.15M | 42.39M | 9.60% |
| Dec 31, 2020 | 441.76M | 102.68M | 30.28% |
| Dec 31, 2019 | 339.08M | 115.27M | 51.50% |
| Dec 31, 2018 | 223.81M | 98.91M | 79.19% |
| Dec 31, 2017 | 124.90M | 107.57M | 620.68% |
| Dec 31, 2016 | 17.33M | 17.27M | 28,311.48% |
| Dec 31, 2015 | 61.00K | -59.00K | -49.17% |
| Dec 31, 2014 | 120.00K | -1.03M | -89.52% |
| Dec 31, 2013 | 1.15M | -3.76M | -76.67% |
| Dec 31, 2012 | 4.91M | 2.84M | 137.40% |
| Dec 31, 2011 | 2.07M | -40.07M | -95.09% |
| Dec 31, 2010 | 42.14M | 35.74M | 558.46% |
| Dec 31, 2009 | 6.40M | 4.81M | 302.45% |
| Dec 31, 2008 | 1.59M | -5.97M | -78.95% |
| Dec 31, 2007 | 7.56M | -578.00K | -7.11% |
| Dec 31, 2006 | 8.13M | -2.82M | -25.77% |
| Dec 31, 2005 | 10.96M | 6.35M | 137.97% |
| Dec 31, 2004 | 4.60M | -2.77M | -37.60% |
| Dec 31, 2003 | 7.38M | 1.10M | 17.57% |
| Dec 31, 2002 | 6.28M | 2.56M | 68.98% |
| Dec 31, 2001 | 3.71M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Option Care Health | 4.21B |
| agilon health | 4.19B |
| QuidelOrtho | 3.12B |
| Sotera Health Company | 990.64M |
| HealthEquity | 971.04M |
| Halozyme Therapeutics | 780.71M |
| Doximity | 448.31M |
| Blueprint Medicines | 216.20M |
ACAD News
- 10 days ago - Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024 - Business Wire
- 13 days ago - Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 18 days ago - Delaware District Court Rules in Favor of Acadia on Formulation Patent Construction (Markman) Claims Regarding NUPLAZID® (pimavanserin) - Business Wire
- 18 days ago - Delaware Federal District Court Rules in Favor of Acadia Pharmaceuticals in NUPLAZID® (pimavanserin) Patent Litigation - Business Wire
- 4 weeks ago - Acadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome - Business Wire
- 4 weeks ago - Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer's Disease Psychosis - Business Wire
- 5 weeks ago - Acadia Pharmaceuticals Announces Change in Research and Development Leadership - Business Wire
- 2 months ago - Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview - Business Wire